Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.
June F. Mullaney, PhD
Advertisement
June F. Mullaney, PhD, is vice-president at the pharmaceutical development technical operations at GlaxoSmithKline, Five Moore Dr., PO Box 13398, Research Triangle Park, NC 27709.
Articles by June F. Mullaney, PhD
Advertisement
Latest Updated Articles
- Available Guidance and Best Practices for Conducting Forced Degradation Studies
Published: February 1st 2002 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Key Trends Driving Supply Chain Localization and Data Scrutiny in Biopharma
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
4
Excipient Innovation, Safer Solvents, and Supply Chain Resilience
5
